Everence Capital Management’s Charles River Laboratories CRL Stock Holding History

Everence Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$331K	Buy	1,916 +637	+50%	+$118K	0.02%	526
2025 Q4	$255K	Hold	1,279	–	–	0.02%	657
2025 Q3	$200K	Sell	1,279 -641	-33%	-$102K	0.01%	770
2025 Q2	$291K	Hold	1,920	–	–	0.02%	595
2025 Q1	$289K	Hold	1,920	–	–	0.02%	580
2024 Q4	$354K	Buy	+1,920	New	+$370K	0.02%	497
2024 Q3	–	Sell	-1,600	Closed	-$366	–	770
2024 Q2	$366	Hold	1,600	–	–	0.03%	473
2024 Q1	$434	Hold	1,600	–	–	0.03%	454
2023 Q4	$378K	Buy	+1,600	New	+$315K	0.03%	502
2022 Q4	–	Sell	-2,140	Closed	-$421K	–	754
2022 Q3	$421K	Hold	2,140	–	–	0.04%	397
2022 Q2	$458K	Hold	2,140	–	–	0.04%	372
2022 Q1	$608K	Hold	2,140	–	–	0.05%	324
2021 Q4	$806K	Buy	+2,140	New	+$831K	0.06%	268

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Everence Capital Management's CRL Position: Q1 2026 in Review

Everence Capital Management increased its Charles River Laboratories (CRL) stake by 50% in Q1 2026, buying an estimated $118K and bringing the position to 1,916 shares worth $331K. The position accounts for 0.02% of the portfolio, ranked #526.

Everence Capital Management first reported a position in CRL in Q4 2021 and has held it in 13 quarters since. The position peaked at $806K in Q4 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Everence Capital Management held 1,916 shares of Charles River Laboratories worth $331K as of Q1 2026.
Everence Capital Management bought 637 Charles River Laboratories shares in Q1 2026, an estimated $118K.
Charles River Laboratories made up 0.02% of Everence Capital Management's portfolio in Q1 2026, its #526 holding.
Everence Capital Management first reported a position in Charles River Laboratories in Q4 2021 and has held it in 13 quarters since.
Everence Capital Management's Charles River Laboratories position peaked at $806K in Q4 2021.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.